Gulnara Patricia Borja-Cabrera

Dr. Gulnara Patricia Borja-Cabrera

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in Vaccine
Verified
Journal Article
Closed access
GBGulnara Patricia Borja-Cabrera
Gulnara Patricia Borja-Cabrera
NPN N Correia Pontes
N N Correia Pontes
VSV O Da Silva
V O Da Silva
ESE Paraguai De Souza
E Paraguai De Souza
WSW R Santos
W R Santos
CSC B Palatnik De Sousa
C B Palatnik De Sousa

1 February 2005 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
IAIngrid Aguilar-Be
Ingrid Aguilar-Be
RZRenata da Silva Zardo
Renata da Silva Zardo
ESEdilma Paraguai de Souza
Edilma Paraguai de Souza
GBGulnara Patricia Borja-Cabrera
Gulnara Patricia Borja-Cabrera
MRMiguel Rosado-Vallado
Miguel Rosado-Vallado
Eric DumonteilEric Dumonteil
Eric Dumonteil
The fucose-mannose ligand (FML) complex ofLeishmania donovaniis a promising vaccine candidate against murine and canine visceral leishmaniasis, and its main component is a 36-kDa nucleoside hydrolase (NH36). In this study, we tested the immune response and protection induced by the purified FML, the recombinant NH36 (rNH36), and NH36 DNA vaccines against the agents of visceral (L. chagasi) and cutaneous (L. mexicana) leishmaniasis in BALB/c mice. Mice developed weak humoral response to the vaccines alone, except for those immunized with FML. However, all three vaccine groups presented elevated immunoglobulin G (IgG), IgG1, and IgG2a levels after infection withL. chagasi, whereas no differences were observed between vaccine and control groups after infection withL. mexicana. A strong intradermal reaction toL. donovaniandL. mexicanaantigens was observed in mice immunized with rNH36 or FML, whereas mice immunized with NH36 DNA only reacted againstL. donovaniantigens. Experimental infection of immunized mice demonstrated that FML and rNH36 induced significant protection againstL. chagasiinfection with reductions in parasite loads of 79%. FML also conferred partial protection againstL. mexicanainfection. The best protection was observed in mice immunized with the VR1012-NH36 DNA vaccine, which induced an 88% reduction inL. chagasiparasite load and a 65% reduction inL. mexicanalesion size. Fluorescence-activated cell sorting analysis indicated the DNA vaccine induced a two- to fivefold increase in gamma interferon-producing CD4+T cells, indicating a Th1-type immune response. Our results showed that the NH36 DNA vaccine induced a strong immunoprotection against visceral and cutaneous leishmaniasis, suggesting that this DNA vaccine represents a very good candidate for use against severalLeishmaniaspecies.

1 March 2006 in Vaccine
Verified
Journal Article
Closed access
ESElvira Saraiva
Elvira Saraiva
ABAndré de Figueiredo Barbosa
André de Figueiredo Barbosa
FSFernanda Nunes Santos
Fernanda Nunes Santos
GBGulnara Patricia Borja-Cabrera
Gulnara Patricia Borja-Cabrera
DNDirlei Nico
Dirlei Nico
CPClarisa Beatriz Palatnik-De-Sousa
Clarisa Beatriz Palatnik-De-Sousa

1 September 2005 in Vaccine
Verified
Journal Article
Closed access
FNF.S. Nogueira
F.S. Nogueira
MMM.A.B. Moreira
M.A.B. Moreira
GBGulnara Patricia Borja-Cabrera
Gulnara Patricia Borja-Cabrera
FSF.N. Santos
F.N. Santos
IMI. Menz
I. Menz
MLM.C.R. Luvizotto
M.C.R. Luvizotto

29 May 2006 in Vaccine
Verified
Journal Article
Closed access
RGR Gamboaleon
R Gamboaleon
EPE Paraguaidesouza
E Paraguaidesouza
GBGulnara Patricia Borja-Cabrera
Gulnara Patricia Borja-Cabrera
FSF Santos
F Santos
LML Myashiro
L Myashiro
CPC Palatnikdesousa
C Palatnikdesousa

1 August 2007 in Vaccine
Verified
Journal Article
Closed access
FSF.N. Santos
F.N. Santos
GBGulnara Patricia Borja-Cabrera
Gulnara Patricia Borja-Cabrera
LML.M. Miyashiro
L.M. Miyashiro
JGJ. Grechi
J. Grechi
ARA.B. Reis
A.B. Reis
CPC.B. Palatnik-De-Sousa
C.B. Palatnik-De-Sousa